cendakimab: Clinical Trials

9 completed. 4 Phase 1, 3 Phase 3, 2 Phase 2.

By phase and status

Phase	Trials	Status
Phase 1	4	Completed 4
Phase 3	3	Completed 3
Phase 2	2	Completed 2

Follow cendakimab: new trials by email Literature Review of cendakimab trials Research Report on cendakimab

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Study to Evaluate the Safety and Tolerability of Cendakimab in Chinese Healthy Participants Cendakimab, Placebo - Healthy Participants	Phase 1	Completed	Bristol-Myers Squibb	25	2023-02-15	2023-08-01
Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis CC-93538 - Eosinophilic Esophagitis	Phase 3	Completed	Celgene	367	2022-08-09	2026-04-06
A Study Evaluating Potential Disease-Mediated Drug-Drug Interaction in Adult Participants With Active Eosinophilic Esophagitis Receiving Cendakimab Cendakimab, CYP substrates - Eosinophilic Esophagitis	Phase 1	Completed	Celgene	16	2022-06-07	2024-12-20
A Study to Evaluate the Drug Levels of Cendakimab Delivered Subcutaneously in Healthy Participants Cendakimab - Healthy Volunteers	Phase 1	Completed	Bristol-Myers Squibb	104	2022-05-02	2023-02-10
A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Japanese Participants With Eosinophilic Gastroenteritis CC-93538, Placebo - Eosinophilic Gastroenteritis	Phase 3	Completed	Celgene	48	2022-03-04	2026-09-14
A Study to Evaluate Safety and Effectiveness of Cendakimab (CC-93538) in Participants With Moderate to Severe Atopic Dermatitis CC-93538, Placebo - Dermatitis, Atopic, Eczema	Phase 2	Completed	Celgene	221	2021-05-14	2024-01-03
A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis CC-93538, Placebo - Eosinophilic Esophagitis	Phase 3	Completed	Celgene	430	2021-02-22	2025-03-13
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis RPC4046, Placebo - Eosinophilic Esophagitis	Phase 2	Completed	Celgene	100	2014-08-31	2017-05-09
Assessment of the Safety of ABT-308 in Healthy Volunteers and Subjects With Asthma ABT-308, Placebo - Asthma	Phase 1	Completed	AbbVie	47	2009-10-01	2017-11-21

Conditions studied

Eosinophilic Esophagitis (4)  ·  Gastroenteritis (3)  ·  Gastrointestinal Diseases (3)  ·  Eosinophilia (2)  ·  Esophageal Diseases (2)  ·  Esophagitis (2)  ·  Hypersensitivity (2)  ·  Asthma (1)  ·  Dermatitis, Atopic (1)  ·  Digestive System Diseases (1)  ·  Eczema (1)  ·  Eosinophilic enteropathy (1)

Sponsors

Celgene (6)  ·  Bristol-Myers Squibb (2)  ·  AbbVie (1)

Countries

United States (6)  ·  Canada (4)  ·  Japan (4)  ·  Poland (3)  ·  Switzerland (3)  ·  Argentina (2)  ·  Australia (2)  ·  Austria (2)  ·  Belgium (2)  ·  China (2)  ·  Germany (2)  ·  Israel (2)  ·  Italy (2)  ·  Portugal (2)  ·  Spain (2)

Top investigators

Andrew Campbell, MD (1)

Results publications

PMID 28455782, PMID 30395812, PMID 32205221, PMID 39018038, PMID 39384067, PMID 40374841, PMID 40985784, PMID 41067281